Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges
Current Atherosclerosis Reports2011Vol. 14(1), pp. 1–10
Citations Over TimeTop 10% of 2011 papers
Related Papers
- → Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome(2008)551 cited
- → Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia(2016)100 cited
- → Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: Randomized comparison of fenofibrate 160mg and niacin 1500mg(2010)23 cited
- → Attainment of combined optimal lipid values with the use of niacin: has AIM-HIGH closed the book on this debate?(2012)1 cited
- → Pleiotropic effects of simvastatin-fenofibrate combination therapy in the subjects with metabolic syndrome(2024)